Prostate cancer screening debates cost my husband his life—and they could cost others theirs too. The conflicting advice surrounding prostate cancer testing is a ticking time bomb, leaving men like my husband confused and vulnerable. In August, I lost my husband to this devastating disease, and reading the recent coverage of the UK National Screening Committee’s recommendations felt like reliving the nightmare. Their stance against widespread screening for most men (Expert panel advises against prostate cancer screening for most men in UK, 28 November, https://www.theguardian.com/society/2025/nov/28/prostate-cancer-screening-not-expected-to-be-made-widely-available-in-uk) echoes the very mixed messages that led to his tragic delay in testing. He avoided the PSA blood test, convinced by conflicting reports that it was unreliable and could lead to unnecessary, harmful treatments. By the time he was diagnosed, the cancer had spread relentlessly, and he passed away just three years later at 68. How can anyone claim the 'harms outweigh the benefits' when the alternative is a death sentence?
The discourse is riddled with contradictions. Dr. Jayne Spink of Prostate Cancer Research passionately advocates for early detection, pointing out that many men remain unaware of their risk until it’s too late (What is prostate cancer and should I be worried if I wee a lot at night? 28 November, https://www.theguardian.com/society/2025/nov/28/what-is-prostate-cancer-and-should-i-be-worried-if-i-wee-a-lot-at-night). Yet, Cancer Research UK aligns with the committee’s cautious approach, arguing there’s insufficient evidence to prove screening does more good than harm (https://www.theguardian.com/society/2025/nov/28/prostate-cancer-screening-not-expected-to-be-made-widely-available-in-uk). Meanwhile, the chair of the Royal College of GPs insists on discussing the 'risks and benefits' of PSA testing with patients. But here’s where it gets controversial: What risks could possibly outweigh the risk of dying unnecessarily? As a widow grappling with this loss, I can’t help but ask: Are we prioritizing theoretical harms over real lives?
I had hoped this public discussion would encourage men to take proactive steps, but I fear it’s doing the opposite. The confusion and mixed messages are paralyzing, not empowering. And this is the part most people miss: Every delay in testing, every moment of hesitation fueled by conflicting advice, could mean the difference between life and death. My husband’s story is a heartbreaking testament to this, and I dread the thought of others facing the same fate.
Let’s be clear: Prostate cancer screening isn’t perfect, but neither is leaving men in the dark. We need clarity, not controversy. What do you think? Is the current approach to prostate cancer screening doing more harm than good? Share your thoughts in the comments—this is a conversation we can’t afford to ignore.
Pat Sharpe
Wandsworth, London
